Centre for Pharmacoepidemiology
The Centre for Pharmacoepidemiology was established in 2005, with the explicit purpose to create a centre of academic excellence in pharmacoepidemiology, to meet the demands from stakeholders in society and industry for expertise and consultation in this field.
The centre, which is still evolving, has since its start met the growing demands, both nationally and internationally, for data on drug safety, drug utilization and rational drug use, including pharmacogenetics. Sweden has through its healthcare registers, biobanks together with high levels of epidemiological, pharmacological and other expertise a unique opportunity to meet these demands. Health care providers, regulatory agencies and the pharmaceutical industry have identified drug safety, and rational drug use together with use of genetics and biomarkers as the most important issues for pharmacoepidemiological research.
CPE has established collaboration with national and international research groups and the centre is part of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and the Nordic network for Pharmacoepidemiology (NorPEN). CPE is working in close collaboration with researchers at the Unit for Clinical Epidemiology at the Department of Medicine and is linked with other groups within epidemiology and pharmacology at Karolinska Institutet.
Prioritized research areas
- Chronic diseases and biologics
- CNS and drugs
- Drugs during pregnancy and infancy
- Cardiovascular diseases and drugs
- Cancer and drugs
